Hosted on MSN11mon
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that ...
pharmaphorum5d
Leo puts target on Dupixent in US as FDA clears tralokinumab
Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis ... who can't control symptoms using topical prescription therapies. The green light comes ...